The stock of Vivos Therapeutics Inc (VVOS) has seen a -18.29% decrease in the past week, with a -42.74% drop in the past month, and a -70.73% decrease in the past quarter. The volatility ratio for the week is 12.46%, and the volatility levels for the past 30 days are at 11.13% for VVOS. The simple moving average for the last 20 days is -33.68% for VVOS stock, with a simple moving average of -62.80% for the last 200 days.
Is It Worth Investing in Vivos Therapeutics Inc (NASDAQ: VVOS) Right Now?
The 36-month beta value for VVOS is also noteworthy at 7.96. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for VVOS is 2.32M, and at present, short sellers hold a 1.13% of that float. The average trading volume of VVOS on April 09, 2024 was 131.33K shares.
VVOS) stock’s latest price update
The stock price of Vivos Therapeutics Inc (NASDAQ: VVOS) has plunged by -8.72 when compared to previous closing price of 3.03, but the company has seen a -18.29% decline in its stock price over the last five trading sessions. Proactive Investors reported 2024-04-09 that Vivos Therapeutics (NASDAQ:VVOS) announced that its CARE oral medical devices for obstructive sleep apnea (OSA) have been approved for Medicare reimbursement. The company said this milestone achievement will allow millions of Medicare beneficiaries coverage and reimbursement for allowable charges billable to Medicare.
VVOS Trading at -44.04% from the 50-Day Moving Average
After a stumble in the market that brought VVOS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -94.33% of loss for the given period.
Volatility was left at 11.13%, however, over the last 30 days, the volatility rate increased by 12.46%, as shares sank -41.45% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -48.33% lower at present.
During the last 5 trading sessions, VVOS fell by -17.58%, which changed the moving average for the period of 200-days by -77.78% in comparison to the 20-day moving average, which settled at $4.07. In addition, Vivos Therapeutics Inc saw -77.77% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at VVOS starting from Huntsman Ronald Kirk, who purchase 14,000 shares at the price of $0.53 back on Jun 20 ’23. After this action, Huntsman Ronald Kirk now owns 86,521 shares of Vivos Therapeutics Inc, valued at $7,420 using the latest closing price.
Huntsman Ronald Kirk, the Chief Executive Officer of Vivos Therapeutics Inc, purchase 15,000 shares at $0.54 during a trade that took place back on Jun 16 ’23, which means that Huntsman Ronald Kirk is holding 72,521 shares at $8,050 based on the most recent closing price.
Stock Fundamentals for VVOS
Current profitability levels for the company are sitting at:
- -1.25 for the present operating margin
- 0.59 for the gross margin
The net margin for Vivos Therapeutics Inc stands at -0.51. The total capital return value is set at -5.03. Equity return is now at value -521.22, with -111.11 for asset returns.
Based on Vivos Therapeutics Inc (VVOS), the company’s capital structure generated 0.83 points at debt to capital in total, while cash flow to debt ratio is standing at -5.99. The debt to equity ratio resting at 4.85. The interest coverage ratio of the stock is 5.24.
Currently, EBITDA for the company is -16.68 million with net debt to EBITDA at -0.02. When we switch over and look at the enterprise to sales, we see a ratio of 0.56. The receivables turnover for the company is 68.32for trailing twelve months and the total asset turnover is 1.29. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.34.
Conclusion
In summary, Vivos Therapeutics Inc (VVOS) has had a bad performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
